Imaging Diagnostic Systems, Inc announced the commencement of a breast cancer imaging study at the Charité, Medical University in Berlin, Germany. The study will examine the potential role of model 1020 CTLM laser breast imaging system as an enhanced breast cancer screening tool when used in combination with the fluorescent dye, Indocyanine Green (ICG). The study will be conducted at the Campus Virchow-Klinikum and the principal investigator is radiologist Dr. Alexander Poellinger.
“In other studies, optical imaging using fluorescent dyes have shown great promise to detect and differentiate malignancies. By using a fluorescent dye in a clinical breast cancer study, we hope to demonstrate an enhancement of the sensitivity and the specificity of diffuse optical tomography. For this purpose we will use a modified CTLM breast scanner that is capable of acquiring both absorption and fluorescence images, stated Dr. Alexander Poellinger.
The ICG fluorescent dye has a distribution pattern in the human body similar to that of extracellular MRI and CT contrast agents and it is already approved for other medical applications. The IDSI model 1020 CTLM scanner that will be used in the study has been specially modified to be able to both excite the ICG dye and image its fluorescence in breast tissue. Following injection of ICG into the patient, the scanner produces 3D images of the localized concentration of the dye. These images are expected to show increased extravasation and accumulation of the dye in malignant tissue.
IDSI users have performed over 15,000 CT Laser Mammography (CTLM) clinical cases worldwide.